Resources from the same session
529MO - Activity, safety and circulating tumour DNA (ctDNA) dynamics of paradox breaker BRAF inhibitor PLX8394 in patients with advanced cancer
Presenter: Mohamed Gouda
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
530MO - Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with low-dose (LD) temozolomide (TMZ)
Presenter: Emiliano Calvo
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
531MO - VHIO immune gene-expression signature (VIGex) to enrich patient selection in immunotherapy (IT) phase I clinical trials
Presenter: Alberto Hernando-Calvo
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
532MO - A phase Ib study of TQB2450 in combination with anlotinib in patients with advanced solid tumour
Presenter: Ying Cheng
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
533MO - Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours
Presenter: Nicolas Girard
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
534MO - First in human study of ONO-4578, a PGE2-receptor EP4 antagonist, in monotherapy and combination with PD-1 checkpoint inhibitor nivolumab in patients with advanced or metastatic solid tumours
Presenter: Noboru Yamamoto
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
535MO - BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma
Presenter: Juan Martin Liberal
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
536MO - A phase I, first-in-human, safety, pharmacokinetic, and pharmacodynamic study of oral dubermatinib (TP-0903) in patients with advanced solid tumours
Presenter: John Sarantopoulos
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
537MO - First-in-human study of JNJ-64619178, a protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced cancers
Presenter: Maria Vieito Villar
Session: Mini Oral - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
Invited Discussant 529MO, 530MO and 531MO
Presenter: Jayesh Desai
Session: Mini Oral - Developmental therapeutics
Resources:
Slides
Webcast